echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Mirogabalin's Phase III study on the treatment of central nervous pain after spinal cord injury has yielded positive results

    Mirogabalin's Phase III study on the treatment of central nervous pain after spinal cord injury has yielded positive results

    • Last Update: 2020-12-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Central nervous pain is caused by sensory neurological lesions or diseases of the central body.
    after a central stroke can occur after a cerebrovascular accident.
    common causes of central nervous pain include spinal cord injury (including spinal cord hollow disease), multiple sclerosis, and trauma brain injury.
    central pain can be spontaneous or stimulating, and may be associated with mechanical pain hypersensitivity and cold pain hypersensitivity.
    Phase III study of central nervous pain after spinal cord injury has reached its main end, the First Third Co., Ltd. announced today.
    the study was conducted in Asia (Japan, South Korea and Taiwan, China) in a double-blind manner to assess the efficacy and safety of Mirogabalin and placebo in patients with central nervous pain after 274 cases of spinal cord injury.
    the main endpoints of the study, which showed changes in pain scores from baseline to week 14, showed mirogabalin better than a placebo.
    addition, no other security concerns were found.
    results of the study will be published in academic conferences and publications.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.